Cadila Healthcare Ltd., a part of the Zydus Group, Friday said its U.S. unit has agreed to acquire the assets of U.S.-based pharmaceutical company Nesher Pharmaceuticals Inc. for an undisclosed amount.Cadila Healthcare said the acquisition of Nesher—the generic unit of KV Pharmaceutical--will allow its U.S. unit to make and sell generic controlled substances in the country, which otherwise cannot be imported.The acquisition includes Nesher's existing and future portfolio of generic drugs, certain manufacturing facilities and a research and development laboratory, Cadila Healthcare said in a statement.The company said the deal entails the assumption of certain liabilities of Nesher, but didn't elaborate.Cadila Healthcare Chairman Pankaj Patel said the development gives the company access to a "difficult-to-develop product pipeline, expertise and infrastructure that will add value to our operations in the U.S."Nesher's pipeline of generic drugs includes eight existing filings with the U.S. drug regulator and five products under development.The deal also includes supply and technical services agreements whereby certain products of KV Pharmaceutical will be manufactured by Zynesher Pharmaceuticals USA LLC, a unit of Zydus Pharmaceuticals USA Inc.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment